I was not able to go forward with a group project at this time. But in particular, me & Aarushi Mishra (both of the same node intend to continue on one after the course)
This project applies the Germinal pipeline — an open-source
computational framework combining AlphaFold-Multimer and the
IgLM antibody language model — to design de novo nanobodies
targeting a defined surface epitope of GFP. Four nanobody
sequences were generated, codon-optimised via Asimov Kernel,
annotated in Benchling, and ordered from Twist Biosciences
as clonal genes for cell-free expression screening on the
Ginkgo Bioworks Nebula platform.
Section 1 — Project Aims
Aim 1 — Experimental (HTGAA scope)
Design, synthesise, and confirm cell-free expression of
de novo anti-GFP nanobodies using the Germinal pipeline
and Ginkgo Bioworks Nebula.
Aim 2 — Development (PhD level)
Apply the validated pipeline to a clinically relevant target
(NKG2D or PD-L1) and validate binding affinity by BLI.
Aim 3 — Visionary
Establish a fully democratised, open-source nanobody
discovery platform accessible to any molecular biology
laboratory without immunisation infrastructure.
Section 2 — Background
Note
**Source paper:** Mille-Fragoso et al. 2025 —
*Efficient generation of epitope-targeted de novo antibodies
with Germinal.* bioRxiv PMC12485712
Germinal achieves experimental success rates of 4–22%
testing only 43–101 designs per target — dramatically
fewer than phage display or random CDR mutagenesis.
Section 3 — Computational Design
Antigen preparation
GFP structure downloaded from PDB (2Y0G), cleaned with
Biopython to remove solvent and chromophore atoms.
Target epitope: residues A169–A171 (surface-exposed,
confirmed by SASA analysis).
Framework
VHH framework from PDB: 1MEL (cAb-Lys3, anti-lysozyme).
Chain A extracted, IMGT-numbered, CDR3 length verified
at 14 residues.
Germinal run
Executed via Tamarind.bio hosted Germinal implementation.
20 designs generated. 4 passing designs selected by
composite score (i_ptm, pLDDT, interface H-bonds,
zero clashes).
All computational tools used in this project are
open-source or HTGAA-partnered.
Tool
Purpose
google collab
All coding and data visualisation
Germinal (Tamarind.bio)
De novo CDR design
Biopython
PDB cleaning + SASA analysis
Asimov Kernel
Codon optimisation
Benchling
Sequence annotation + storage
SecureDNA
Biosafety screening
Twist Biosciences
Clonal gene synthesis
Ginkgo Nebula
Cell-free expression screening
py3Dmol
Structure visualisation
Expression construct
Vector: pTwist Amp High Copy
System: E. coli cell-free (PURExpress)
Detection: Anti-His HRP Western blot
Purification: Ni-NTA magnetic beads
Binding: GFP pulldown assay
Section 6 — Ethical Considerations
Warning
All synthesised sequences are planned to be screened through
SecureDNA prior to ordering. No biosecurity concerns
identified — GFP is a non-pathogenic model antigen.
This project applies the principles of beneficence
(reducing animal use in antibody generation) and
justice (democratising access to molecular tools).
All work will be conducted at BSL-1. No human subjects involved.
References
Mille-Fragoso et al. (2025) bioRxiv PMC12485712
Bennett et al. (2024) Science 385(6707)
Liu et al. (2020) NEJM 382:545
Evans et al. (2022) AlphaFold-Multimer bioRxiv
Shuai et al. (2023) Cell Syst 14:979
Group Final Project
I was not able to go forward with a group project at this time. But in particular, me & Aarushi Mishra (both of the same node intend to continue on one after the course)